{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:34:32Z","timestamp":1795059272348,"version":"4.10.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","biologicalpsychiatryjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.biopsych.2021.02.966","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T09:55:30Z","timestamp":1614333330000},"page":"236-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-4625","authenticated-orcid":false,"given":"Mary E.","family":"Kelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Sueng","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-1647","authenticated-orcid":false,"given":"Justin K.","family":"Rajendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Edward","family":"Craighead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Rakofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boadie W.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen S.","family":"Mayberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2021.02.966_bib1","doi-asserted-by":"crossref","first-page":"107557","DOI":"10.1016\/j.pharmthera.2020.107557","article-title":"Predicting treatment effects in unipolar depression: A meta-review","volume":"212","author":"Gillett","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2021.02.966_bib2","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3390\/ijms21062148","article-title":"Neuroimaging biomarkers for predicting treatment response and recurrence of major depressive disorder","volume":"21","author":"Kang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.biopsych.2021.02.966_bib3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.drudis.2014.02.002","article-title":"Are there meaningful biomarkers of treatment response for depression?","volume":"19","author":"Breitenstein","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.biopsych.2021.02.966_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11920-019-1072-6","article-title":"Intrinsic brain network biomarkers of antidepressant response: A review","volume":"21","author":"Dunlop","year":"2019","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.biopsych.2021.02.966_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2012.05.008","article-title":"Predictive neural biomarkers of clinical response in depression: A meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies","volume":"52","author":"Fu","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.biopsych.2021.02.966_bib6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/cns.13048","article-title":"Machine learning in major depression: From classification to treatment outcome prediction","volume":"24","author":"Gao","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.biopsych.2021.02.966_bib7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamapsychiatry.2013.143","article-title":"Toward a neuroimaging treatment selection biomarker for major depressive disorder","volume":"70","author":"McGrath","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1176\/appi.neuropsych.14030048","article-title":"Preliminary findings supporting insula metabolic activity as a predictor of outcome to psychotherapy and medication treatments for depression","volume":"27","author":"Dunlop","year":"2015","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2021.02.966_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamapsychiatry.2020.2549","article-title":"Prediction, not association, paves the road to precision medicine","volume":"78","author":"Bzdok","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpsychires.2017.09.002","article-title":"Genetic testing as a supporting tool in prescribing psychiatric medication: Design and protocol of the IMPACT study","volume":"96","author":"Herbert","year":"2018","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.biopsych.2021.02.966_bib11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.15r10583","article-title":"Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies","volume":"78","author":"Rosenblat","year":"2017","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib12","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1161\/01.STR.0000185718.26377.07","article-title":"Applying a phase II futility study design to therapeutic stroke trials","volume":"36","author":"Palesch","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.biopsych.2021.02.966_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.biopsych.2021.02.966_bib14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.20968","article-title":"A\u00a0multicenter phase II study of bortezomib in recurrent or metastatic sarcomas","volume":"103","author":"Maki","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.biopsych.2021.02.966_bib15","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.31234","article-title":"Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56\/07)","volume":"124","author":"Montemurro","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.biopsych.2021.02.966_bib16","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/cncr.32046","article-title":"Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer","volume":"125","author":"Sherman","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.biopsych.2021.02.966_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.biopsych.2013.12.005","article-title":"Pretreatment brain states identify likely nonresponse to standard treatments for depression","volume":"76","author":"McGrath","year":"2014","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A\u00a0rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1176\/ajp.2007.164.5.778","article-title":"Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial","volume":"164","author":"Kennedy","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"suppl 4","key":"10.1016\/j.biopsych.2021.02.966_bib20","first-page":"53","article-title":"Remission versus response: The new gold standard of antidepressant care","volume":"65","author":"Keller","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\u2217D: Implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib22","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/archgenpsychiatry.2009.144","article-title":"Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: The REVAMP Trial","volume":"66","author":"Kocsis","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib23","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM200005183422001","article-title":"A\u00a0comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression [published correction appears in N Engl J Med 2001; 345:232","volume":"342","author":"Keller","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biopsych.2021.02.966_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jpsychires.2011.11.003","article-title":"Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder","volume":"46","author":"Dunlop","year":"2012","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.biopsych.2021.02.966_bib25","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1078-0432.CCR-19-3060","article-title":"A\u00a0phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed stage IV squamous cell lung cancers","volume":"26","author":"Paik","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopsych.2021.02.966_bib26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/03610920008832524","article-title":"Optimal two-stage designs for phase II clinical trials with differentiation of complete and partial responses","volume":"29","author":"Lin","year":"2000","journal-title":"Commun Stat Theor Methods"},{"key":"10.1016\/j.biopsych.2021.02.966_bib27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1176\/appi.ajp.2016.16050517","article-title":"Effects of patient preferences on outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study","volume":"174","author":"Dunlop","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2014.12.018","article-title":"The international Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment","volume":"61","author":"Saveanu","year":"2015","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.biopsych.2021.02.966_bib29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/sim.1653","article-title":"On the estimation of the binomial probability in multistage clinical trials","volume":"23","author":"Jung","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.biopsych.2021.02.966_bib30","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/sim.3123","article-title":"Proper inference from Simon\u2019s two-stage designs","volume":"27","author":"Koyama","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.biopsych.2021.02.966_bib31","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2217\/pgs.15.56","article-title":"BDNF\/TRKB\/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients","volume":"16","author":"Colle","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopsych.2021.02.966_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/mp.2008.116","article-title":"Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder","volume":"15","author":"Kato","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jad.2018.08.058","article-title":"Differentiating responders and non-responders to rTMS treatment for depression after one week using resting EEG connectivity measures","volume":"242","author":"Bailey","year":"2019","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.biopsych.2021.02.966_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1176\/appi.ajp.2019.18070870","article-title":"Effect of intrinsic patterns of functional brain connectivity in moderating antidepressant treatment response in major depression","volume":"177","author":"Chin Fatt","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamapsychiatry.2016.3730","article-title":"Leveraging statistical methods to improve validity and reproducibility of research findings","volume":"74","author":"Blackford","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2021.02.966_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/07474946.2019.1611307","article-title":"Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping","volume":"38","author":"Shan","year":"2019","journal-title":"Seq Anal Des Methods Appl"}],"updated-by":[{"DOI":"10.1016\/j.biopsych.2021.04.020","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000}}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322321010957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322321010957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T12:14:58Z","timestamp":1658492098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322321010957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0006322321010957"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2021.02.966","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2021.02.966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}